Drug Development

GSK’S B vaccine prevents harmful disease among children; U.S FDA applauds

9th February 2018

GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero...

Janssen Pierce To Globally Collabrate With Theravance Biopharma For Oral, Pan-Jak Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease

by Content Team

9th February 2018

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of...

Roche’s TECENTRIQ®and Avastin® reduced the risk of disease worsening or death by 26 percent in certain advanced kidney cancer cases

by Content Team

9th February 2018

Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment...

Shire presentations at EAHAD 2018 demonstrate commitment to studying outcomes in patients with bleeding disorders

by Content Team

8th February 2018

Shire plc , the global biotechnology leader in rare diseases, today announced the range of real-world and long-term research it...

Treatment and Management of Rare Lysosomal Diseases highlighted by shire at Global Conference

by Content Team

8th February 2018

Shire plc the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters...

Positive Results from the Pivotal Phase III ‘OPTIMISMM’ Study of POMALYST/IMNOVID

by Content Team

8th February 2018

Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically...